Not exact matches
The new offering, «Watson for Patient Safety,» will gobble up anonymized medical records, claims
data, and millions of electronic submissions to the FDA
about potential drug side effects (known as individual case safety reports) to see if it can learn
about the hidden dangers of
medicines before they become too costly.
However he seems extra cranky... The
data online seems to only be
about how much
medicine comes through in the milk and whether it's dangerous (seemingly not) but not
about the effect the «safe» amount has on the baby.
From 1988 - 1991, I collected interview
data on the self - and body - images of 40 professional women and homebirthers in relation to their beliefs and choices
about pregnancy and birth, and published that study in Social Science and
Medicine and elsewhere.
To guide the spending of that money, the National Institute of
Medicine made a priority list of situations for which
data about outcomes are badly needed — for instance, comparing the effectiveness of various medical and behavioral interventions to prevent the elderly from falling (the complications of which are a leading cause of death), comparing assorted drugs and surgeries alone or in combination in the treatment of specific cancers, comparing the effectiveness of different implants and devices for treating hearing loss, and so forth.
The documentation ranges across the whole spectrum of drug development: Investigators» brochures provide information on all that is currently known
about the
medicine and so need periodic updating; accurate and concise protocols are required to ensure that trials are performed effectively; clinical trial reports (generally from phase II and III studies) present the information gathered from the trials; higher level documents provide summaries of efficacy and safety
data from clinical trial programmes; expert reports provide critical interpretation of the results; and response documents clarify any points that are not clear to the regulatory agencies or provide additional analyses or supporting
data for any items of concern.
«We spend a lot of time thinking
about traditional risk factors for stroke such as high blood pressure, cholesterol, diabetes and smoking — but our
data underscore the possibility that everyday air pollution may also pose a significant stroke risk,» said senior investigator Jeffrey S. Berger, MD, an assistant professor in NYU Langone Medical Center in the Department of
Medicine, Leon H. Charney Division of Cardiology.
«The foundation of P4
medicine is the idea that in the near future we will have the tools to reduce enormously complex
data from 300 million Americans to simple hypotheses
about health and disease for each individual,» he says.
The study, published Monday in the Journal of the American Board of Family
Medicine, tapped a U.S. health survey that gathered
data from providers and facilities on prescription medications, health status, and basic demographics for
about 51,000 adults.
Researchers at Rice University, Baylor College of
Medicine and their colleagues used
data from such maps to develop a statistical approach that reveals details
about brains» internal networks.
I sat down with Mike Draugelis, former Lockheed Martin missile defense engineer turned Penn
Medicine's Chief
Data Scientist, to learn a bit more about the topic, the use of big data in health care and beyond, and the future of the indus
Data Scientist, to learn a bit more
about the topic, the use of big
data in health care and beyond, and the future of the indus
data in health care and beyond, and the future of the industry.
About the Center for
Data Intensive Science The Center for Data Intensive Science (CDIS) at the University of Chicago is developing the science of data and its applications to biology, medicine, healthcare, and the environm
Data Intensive Science The Center for
Data Intensive Science (CDIS) at the University of Chicago is developing the science of data and its applications to biology, medicine, healthcare, and the environm
Data Intensive Science (CDIS) at the University of Chicago is developing the science of
data and its applications to biology, medicine, healthcare, and the environm
data and its applications to biology,
medicine, healthcare, and the environment.
«These generous gifts enable us to take a major step forward in realizing the promise of
data collection and analysis on a massive scale, and bringing the discoveries it yields into the day - to - day practice of
medicine,» said Robert Zimmer, president of the University of Chicago, who spoke
about the institution's strategic vision as a place for translational discovery.
About M2Gen ® M2Gen ® is Moffitt Cancer Center's wholly owned, for - profit, informatics solution subsidiary advancing personalized
medicine by using high quality tissue, clinical
data and molecular technology to accelerate the discovery and delivery of personalized
medicine.
Point 3 in the list of eight priorities for the year ahead are to «work alongside others to encourage proper sharing of
data in genomic
medicine and to contribute to the thinking
about how patients should be engaged
about this».
In the new study, which appears in the Archives of Internal
Medicine, researchers in Europe and North America analyzed
data from eight randomized controlled trials that included
about 37,500 people who had heart disease, or were considered to be at risk.
In the new study, which was published in the Archives of Internal
Medicine, Dr. Huang and her colleagues re-analyzed
data from a study that included
about 150 overweight and obese menopausal women who were experiencing urinary incontinence as well as troublesome hot flashes.
Most people might think shelter
medicine is mostly
about spay / neuter, but a group of progressive veterinarians are changing paradigms all over the United States as they develop innovative,
data - driven strategies for helping homeless pets.
We are also collecting
data from shelter and rescue directors
about shelter
medicine within your organization.
Dr. Jan Scarlett, DVM, MPH, PhD, and Director of Maddie's ® Shelter
Medicine Program at Cornell, talks
about what types of
data to track and what metrics to calculate and monitor at the ASPCA / Maddie's ® Shelter
Medicine Conference 2012.
Study leader Jon Jureidini said it raised wider implications
about the need for medical researchers to publish their underlying
data — standard practice in genomics and astronomy, but rare in
medicine.»
A paper reporting a «rigorous double blind» study — the VIGOR trial — was submitted to NEJM in 1998, got through peer review at one of the most up - tight journals in the world of
medicine, and — by way of cherry - picking the
data submitted (selecting out some study subjects whose adverse events histories which, if considered, would've significantly affected the safety profile for rofecoxib and revealed something that Merck really didn't want us prescribers to learn
about their «blockbuster» product — was published to be touted by Merck's marketing weevils as solid proofs of Vioxx's tolerability, efficacy, and safety.
Another speaker, Denis Horgan, the European Alliance for Personalised
Medicine's executive director, said the event was an opportunity to discuss Big
Data and advances in genetics together with patient involvement in decision - making
about their own treatment.
Billings Montana
About Blog My blog about becoming a Healthcare Data Scientist, Healthcare Big Data and Analytics, Healthcare Predictive Analytics, Infographics, and assorted Emergency Medicine / Learning Health System / Complexity Science to
About Blog My blog
about becoming a Healthcare Data Scientist, Healthcare Big Data and Analytics, Healthcare Predictive Analytics, Infographics, and assorted Emergency Medicine / Learning Health System / Complexity Science to
about becoming a Healthcare
Data Scientist, Healthcare Big
Data and Analytics, Healthcare Predictive Analytics, Infographics, and assorted Emergency
Medicine / Learning Health System / Complexity Science topics.
About Blog Seven Bridges is the biomedical
data analysis company accelerating breakthroughs in genomics research for cancer, drug development and precision
medicine.